QTERN Dosage
Generic name: DAPAGLIFLOZIN 10mg, SAXAGLIPTIN HYDROCHLORIDE 5mg
Dosage form: tablet, film coated
Drug class: Antidiabetic combinations
Medically reviewed by Drugs.com. Last updated on Oct 13, 2022.
Prior to Initiation of QTERN
Assess renal function prior to initiation of QTERN therapy and periodically thereafter [see WARNINGS AND PRECAUTIONS (5.4)].
Assess volume status and, if necessary, correct volume depletion prior to initiation of QTERN [see WARNINGS AND PRECAUTIONS (5.4) and USE IN SPECIFIC POPULATIONS (8.5, 8.6)].
Dosage
For patients not already taking dapagliflozin, the recommended starting dose of QTERN is a 5 mg dapagliflozin/5 mg saxagliptin tablet taken orally once daily in the morning with or without food.
In patients tolerating 5 mg dapagliflozin and 5 mg saxagliptin once daily who require additional glycemic control, the QTERN dose can be increased to 10 mg dapagliflozin/5 mg saxagliptin tablet once daily in the morning with or without food.
Swallow whole. Do not crush, cut or chew QTERN tablets.
Patients with Renal Impairment
No dose adjustment is needed in patients with an estimated glomerular filtration rate (eGFR) greater than or equal to 45 mL/min/1.73 m2.
QTERN is contraindicated in patients with an eGFR less than 45 mL/min/1.73 m2 [see CONTRAINDICATIONS (4) and USE IN SPECIFIC POPULATIONS (8.6)].
Use with Strong CYP3A4/5 Inhibitors
Do not coadminister QTERN with strong cytochrome P450 3A4/5 inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) [see DRUG INTERACTIONS (7)].
Frequently asked questions
More about Qtern (dapagliflozin / saxagliptin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (6)
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antidiabetic combinations
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.